[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
January 7, 1998

Rezulin Labeling Updated to Recommend More Frequent Patient Monitoring

Author Affiliations

Not Available

Not Available

JAMA. 1998;279(1):9. doi:10.1001/jama.279.1.9

Updated labeling for troglitazone (Rezulin, Parke-Davis, Morris Plains, NJ) includes a new recommendation that liver enzyme levels should be measured in patients initially, then monthly for the first 6 months of treatment, every other month for the next 6 months, and periodically thereafter. The new labeling also makes the warning regarding potential liver toxicity more prominent and updates the effectiveness information to state that monotherapy should be discontinued if effective results are not achieved after a 6- to 8-week trial.

First Page Preview View Large
First page PDF preview
First page PDF preview